Before the Bell
$
43.40
Change
-0.15 -0.34%
Volume
Volume 7,325
Jan 31, 2023, 4:50 a.m.
Real time quotes
Previous close
$ 43.55
$ 43.55
Change
-0.24 -0.55%
Day low
Day high
$43.40
$44.14

52 week low
52 week high
$41.45
$56.32

Market cap
$245.81B
Average volume
21.36M
P/E ratio
8.39
Rev. per Employee
$1.26M
EPS
5.19
Dividend
0.41
Div yield
3.77%
Ex dividend date
1/26/23
MarketWatch News on PFE
-
Biden to end COVID-19 emergency declarations on May 11
- Associated Press
-
Johnson & Johnson stock falls Monday, underperforms market
- MarketWatch Automation
-
Moderna Inc. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
What Pfizer's Earnings Will Say About Covid-19 Vaccine Sales
- Josh Nathan-Kazis
-
- Janet H. Cho
-
Apple, Amazon, Fed Decision, Jobs, and More
- Nicholas Jasinski
-
Johnson & Johnson stock outperforms competitors despite losses on the day
- MarketWatch Automation
-
Moderna Inc. stock falls Friday, underperforms market
- MarketWatch Automation
-
FDA Advisers Recommend Replacing All Covid Vaccines With Bivalent Version
- Josh Nathan-Kazis
-
Johnson & Johnson stock falls Thursday, underperforms market
- MarketWatch Automation
-
Moderna Inc. stock rises Thursday, still underperforms market
- MarketWatch Automation
-
Pfizer downgraded to neutral from buy at UBS
- Tomi Kilgore
-
Johnson & Johnson stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Moderna Inc. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Weight-Loss Medicines Are Supercharging Drugmakers
- Bill Alpert
-
Johnson & Johnson stock remains steady Tuesday, still outperforms market
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Johnson & Johnson: Analyst Recommendations and Target Price
- MarketRealist.com
-
Analyst Recommendations for Teva Pharmaceutical in July
- MarketRealist.com
-
Analysts’ Latest Recommendations on Mylan
- MarketRealist.com
Other News on PFE
-
How Biden Officials Bungled a Better Vaccine
- Allysia Finley
-
FDA Advisers Back Annual Covid-19 Boosters With Reservations About Rollout
- Liz Essley Whyte
-
Johnson & Johnson Profit Falls 25%
- Peter Loftus
-
The Deceptive Campaign for Bivalent Covid Boosters
- Allysia Finley
-
Moderna Finds Life After Covid-19
- David Wainer
-
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them
- Jared S. Hopkins
-
Twitter Offers Free Ads as It Seeks to Win Back Advertisers
- Suzanne Vranica
-
J&J Slashes Production of Its Covid-19 Vaccine
- Jared S. Hopkins
-
China’s Shortage of Antivirals Puts Vulnerable People at Risk
- Raffaele Huang
-
Where Are the Next Covid Treatments?
- The Editorial Board
-
Moderna Considers Price of $110-$130 for Covid-19 Vaccine
- Peter Loftus
-
As the U.S. Gets Older, Some ETFs Bet on Aging in Place
- Bailey McCann
-
China to Allow Rapid Tests to Confirm Covid Cases
- Rachel Liang
-
- TheNewswire.ca
- Loading more headlines...
Press Releases on PFE
-
Top stocks to focus on Thursday (RSCZF,LUV,TSLA,CVX,LEVI,CMCSA)
- Investor Brand Media
-
- Stock Traders Daily
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com